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ARTICLE
Intron-containing RNA from the HIV-1 provirus
activates type I interferon and inﬂammatory
cytokines
Sean Matthew McCauley1, Kyusik Kim 1, Anetta Nowosielska 1, Ann Dauphin1, Leonid Yurkovetskiy 1,
William Edward Diehl 1 & Jeremy Luban 1,2
HIV-1-infected people who take drugs that suppress viremia to undetectable levels are pro-
tected from developing AIDS. Nonetheless, HIV-1 establishes proviruses in long-lived CD4+
memory T cells, and perhaps other cell types, that preclude elimination of the virus even after
years of continuous antiviral therapy. Here we show that the HIV-1 provirus activates innate
immune signaling in isolated dendritic cells, macrophages, and CD4+ T cells. Immune acti-
vation requires transcription from the HIV-1 provirus and expression of CRM1-dependent, Rev-
dependent, RRE-containing, unspliced HIV-1 RNA. If rev is provided in trans, all HIV-1 coding
sequences are dispensable for activation except those cis-acting sequences required for
replication or splicing. Our results indicate that the complex, post-transcriptional regulation
intrinsic to HIV-1 RNA is detected by the innate immune system as a danger signal, and that
drugs which disrupt HIV-1 transcription or HIV-1 RNA metabolism would add qualitative
beneﬁt to current antiviral drug regimens.
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There are currently over 40 antiretroviral drug formulationsthat block essential steps in the HIV-1 replication cycle,including reverse transcription, integration, and proteolytic
processing of the viral polyproteins1,2. Although these treatments
are effective at reducing viremia, HIV-1 establishes proviruses in
long-lived CD4+ memory T cells, and perhaps other cell types3–5,
that preclude elimination of the virus even after years of con-
tinuous antiviral therapy6. As a result, HIV-1-infected individuals
must maintain a strict regimen of antiviral drugs or risk viral
rebound and development of HIV-1 drug resistance6–9. Fur-
thermore, despite the drastic reduction in viral replication,
these individuals sometimes exhibit chronic inﬂammation asso-
ciated with heightened risk of cardiovascular pathology10–12.
Though the majority of proviruses that persist during antiviral
therapy are defective for the production of infectious virions13,
many proviruses are expressed, raising the possibility that the
HIV-1 provirus, or its transcripts, contribute to ongoing
inﬂammation14.
HIV-1 exploits a number of host and viral factors to avoid
detection by the innate immune system15. Innate immune
detection of HIV-1 has been reported to occur via a variety of
mechanisms. Early after encounter with a target cell, HIV-1 CA
interaction with host TRIM516,17, or, independently, HIV-1
gp4118, activates transforming growth factor beta-activated kinase
1 (TAK1)-dependent signaling pathways. Plasmacytoid dendritic
cells (pDCs) readily detect HIV-1 RNA via TLR7 and produce
copious levels of type I interferon19–21. HIV-1 genomic RNA
has also been reported to activate RIG-I signaling22,23, and
HIV-1 cDNA can be detected by the cytoplasmic DNA sensor
cGAS24–26. Sensing of HIV-1 infection has also been suggested to
occur following integration, with critical determinants including
HIV-1 capsid27, post-integration cGAS signaling25, and abortive
HIV-1 RNA transcripts28.
The determinants for innate immune detection of HIV-1 were
investigated in detail here. To start, dendritic cells were chal-
lenged with a large panel of single-cycle HIV-1 vectors. The
results show that high-level activation of innate immune gene
expression in transduced cells requires integration, as well as
transcription from the provirus. Furthermore, DC maturation is
dependent upon Rev-CRM1-mediated export of intron-bearing,
HIV-1 genomic RNA. Transduced macrophages and CD4+
T cells behave like transduced DCs. Primary HIV-1 clones in the
context of complete, replication-competent HIV-1 also give
similar results. The observations reported here demonstrate that
the innate immune system detects HIV-1’s unique modes of RNA
processing and suggest that inhibitors of HIV-1 transcription or
HIV-1 RNA metabolism would be beneﬁcial additions to current
retroviral therapy.
Results
Dendritic cells mature in response to challenge with HIV-1. To
determine if HIV-1 proviruses activate innate immune signaling,
human blood cells were transduced with single-cycle vectors,
either a full-length, single-cycle HIV-1 clone with a frameshift in
env and eGFP in place of nef (HIV-1-GFP)29, or a minimal 3-part
lentivector encoding GFP (Fig. 1a, and Supplementary Table 1)16.
Monocyte derived dendritic cells (DCs) were challenged initially
since HIV-1 transduction of these specialized antigen-presenting
cells activates innate immune signaling23,24,27,30,31. To increase
the efﬁciency of provirus establishment, vectors were pseudo-
typed with the vesicular stomatitis virus glycoprotein (VSV G)
and delivered concurrently with virus-like particles (VLPs)
bearing SIVMAC251 Vpx (Fig. 1b)16,32. Transduction efﬁciency, as
determined by ﬂow cytometry for GFP-positive cells, was 30-60%
(Fig. 1b and Supplementary Fig 1a), depending on the blood
donor.
DCs matured in response to HIV-1-GFP transduction, as
indicated by increased mean ﬂuorescence intensity of co-
stimulatory or activation molecules, including HLA-DR, CD80,
CD86, CD40, CD83, CCR7, CD141, ISG15, MX1, and IFIT133
(Fig. 1b, c and Supplementary Fig. 1a, b). Identical results were
obtained with full-length, single-cycle vectors generated from
primary, transmitted/founder clones that were derived by single
genome sequencing, HIV-1AD1734, HIV-1Z331M-TF35, and HIV-
1ZM249M36, the ﬁrst virus being clade B, the other two clade C
(Fig. 1d and Supplementary Fig. 1c). A single cycle HIV-2 vector
induced maturation, indicating that this innate response was not
unique to HIV-1 (Fig. 1e and Supplementary Fig. 1d).
Maturation was evident among both GFP positive and negative
cells (Fig. 1b), the latter likely resulting from activation in trans by
type 1 IFN as others have shown27,31. To test this idea, naive DCs
were incubated with ﬁltered supernatant from autologous DCs
that had been transduced previously with HIV-1-GFP. Super-
natant from DCs transduced with HIV-1-GFP, but not with
minimal lentivector, upregulated CD86 and ISG15 on the naive
DCs (Fig. 1f and Supplementary Fig 1e). Maturation activity was
evident at a 1:1000 dilution of supernatant to which nevirapine
had been added to preclude carry-over of transduction-
competent HIV-1-GFP.
DCs matured when HIV-1-GFP transduction efﬁciency was
augmented with nucleosides37, rather than with SIV VLPs,
indicating that Vpx was not required for maturation (Fig. 1g
and Supplementary Fig. 1f). DCs were then challenged with
replication-competent HIV-1 bearing CCR5-tropic Env, either T
cell-tropic or macrophage-tropic38, with or without Vpx-VLPs
(Fig. 1h and Supplementary Fig. 1g). The percent of cells
transduced by vector bearing either Env increased with Vpx,
though DC maturation was observed under all conditions, even
among the very few DCs transduced by T cell-tropic env (see inset
of Fig. 1h). These results indicate that neither VSV G, nor Vpx,
nor high-titer infection, was required for DC maturation.
In response to transduction with HIV-1-GFP, steady-state
CXCL10, IFNB1, and IL15 mRNAs reached maximum levels at 48
h, increasing 31,000-, 92-, and 140-fold relative to mock-treated
cells, respectively (Fig. 1i, j). Correspondingly, IFNα2, CCL7, IL-6,
CXCL10, and TNFα proteins accumulated in the supernatant
(Fig. 1k). In contrast to the results with HIV-1-GFP, there were no
signs of maturation after transduction with the 3-part minimal
lentivector (Fig. 1b, j, k and Supplementary Fig. 1a, b, c, d).
DC maturation requires reverse transcription and integration.
To determine if early stages in the HIV-1 replication cycle were
necessary for maturation, reverse transcription was inhibited by
nevirapine (NVP) or the HIV-1 RT mutant D185K/D186L, and
integration was inhibited with raltegravir (RALT) or the HIV-1
IN mutant D116A (Supplementary Tables 1 and 2), as previously
described39. Each of these four conditions abrogated maturation,
as indicated by cell surface CD86 (Fig. 2a, and Supplementary
Fig. 2a) and steady-state CXCL10 mRNA (Fig. 2b). When inte-
gration was inhibited, CXCL10 mRNA increased in response to
challenge with HIV-1-GFP, but levels were nearly 1,000 times
lower than when integration was not blocked (Fig. 2b). As an
additional control, DCs challenged with the well-characterized,
non-infectious, protease active-site mutant D25A40 expressed
10,000 times less CXCL10 mRNA than did cells transduced with
HIV-1-GFP (Fig. 2b).
HIV-1 virion RNA and newly synthesized viral cDNA are
reported to be detected by RIG-I and by cGAS, respectively23,24.
Signal transduction downstream of both sensors requires TBK1
and IRF3. The TBK1 inhibitor BX795 (Supplementary Table 2)
blocked DC maturation in response to cGAMP but had no effect
on maturation after HIV-1-GFP transduction (Fig. 2c and
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Supplementary Fig. 2b). Moreover, IRF3 knockdown (Supple-
mentary Table 1)16 suppressed activation of CD86 or ISG15 in
response to cGAMP, but not in response to HIV-1 transduction
(Fig. 2c and Supplementary Fig. 2b). Similarly, no effect on HIV-
1-induced DC maturation was observed with knockdown of IRF1,
5, 7, or 9, or of STAT1 or 2, Supplementary Table 1)16, or of
pharmacologic inhibition of CypA, PKR, c-Raf, IkBa, NF-kB,
MEK1+ 2, p38, JNK, Caspase 1, pan-Caspases, ASK1, eIF2a,
TBK1, IKKe, TAK1, or NLRP3 (Supplementary Table 2). Under
the conditions used here, then, DC maturation required reverse
transcription and integration but was independent of most well
characterized innate immune signaling pathways.
Provirus transcription is required for innate activation. Com-
pletion of the HIV-1 integration reaction requires cellular DNA
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repair enzymes41. That DCs did not mature in response to
transduction with minimal lentivectors (Fig. 1b, j, k) indicates
that activation of the DNA repair process is not sufﬁcient, and
that transcription from the HIV-1-GFP provirus must be neces-
sary for maturation. Indeed, gag expression from an integrated
vector has been reported to be necessary for DC maturation27. To
determine if any individual HIV-1 proteins were sufﬁcient to
mature DCs, a minimal lentivector was used to express codon
optimized versions of each of the open reading frames possessed
by HIV-1-GFP (Fig. 2d, Supplementary Fig. 2b, and Supple-
mentary Table 1). Among these vectors was a gag-expression
vector that produced as much p24 protein as did HIV-1-GFP
(Fig. 2d). None of these vectors matured DCs (Fig. 2d and Sup-
plementary Fig. 2d).
HIV-1-GFP was then mutated to determine if any protein
coding sequences were necessary for DC maturation. For these
and any subsequent experiments in which an essential viral
component was disrupted within HIV-1-GFP, the factor in
question was provided in trans, either during assembly in
transfected HEK293 cells, or within transduced DCs, as
appropriate (see Methods). Mutations that disrupted both gag
and pol, either a double frameshift in gag, or a mutant in which
the ﬁrst 14 ATGs in gag were mutated, abolished synthesis of CA
(p24) yet retained full maturation activity (Fig. 2e, Supplementary
Fig. 2e, and Supplementary Table 1). Deletion mutations
encompassing gag/pol, vif/vpr, vpu/env, or nef/U3-LTR, each
designed so as to leave cis-acting RNA elements intact, all
matured DCs (Fig. 2f, Supplementary Fig. 2e, and Supplementary
Table 1). These results indicate that these HIV-1-GFP RNA
sequences, as well as the proteins that they encode, were not
required for DC maturation.
Tat and Rev coding sequences were individually disrupted by
combining start codon point mutations with nonsense codons
that were silent with respect to overlapping reading frames
(Supplementary Table 1). Neither Δtat nor Δrev matured DCs
upon transduction (Fig. 2g and Supplementary Fig. 2f). However,
DCs matured upon co-transduction of Δtat and Δrev, or when
minimal lentivectors expressing codon-optimized Tat and Rev
were co-transduced in trans (Fig. 2g and Supplementary Fig. 2g).
These results indicate that the maturation defect with the
individual vectors was due to disruption of Tat and Rev function,
and not due to a cis-acting defect of the mutant RNA.
The minimal 3-part lentivector expressed GFP from a
heterologous promoter and had a deletion mutation encompass-
ing the essential, cis-acting TATA box and enhancer elements42,
as well as in the trans-acting tat and rev, that inactivated the
promoter in the proviral 5′ LTR (Fig. 1a). To test the importance
of LTR-driven transcription for DC maturation by the HIV-1
provirus, the HIV-1 LTR was restored in the minimal vector
(Fig. 2h, Supplementary Fig. 2g, and Supplementary Table 1); in
addition, GFP was inserted in place of gag as a marker for LTR
expression, and the heterologous promoter was used to drive tat,
rev, or both genes separated by P2A coding sequence (Fig. 2h).
None of the LTR-driven, minimal vectors matured DCs (Fig. 2h
and Supplementary Fig. 2g).
To determine if tat was necessary for DC maturation, tat and
TAR were mutated in HIV-1-GFP and the LTR promoter was
modiﬁed to be tetracycline-inducible, as previously described43
(Tet-HIV-1 in Fig. 3a and Supplementary Table 1). The
doxycycline-dependent reverse transactivator (rtTA) was deliv-
ered in trans by lentivector. In the presence of doxycycline
(Supplementary Table 2), Tet-HIV-1 and rtTA matured DCs
when given in combination, but neither vector matured DCs
when given in isolation (Fig. 3a and Supplementary Fig. 3a).
Additionally, the magnitude of cell surface CD86 was dependent
on the doxycycline concentration, indicating that maturation was
dependent on the level of HIV-1 transcription (Fig. 3b and
Supplementary Fig. 3b). These results demonstrated that tat was
not required for maturation, so long as the provirus was
expressed.
Rev-CRM1-mediated RNA export is necessary for activation.
To ascertain whether rev was necessary for DC maturation, the
RTE from a murine intracisternal A-particle retroelement (IAP),
and the CTE from SRV-1, were inserted in place of nef (HIV-
RTE/CTE in Fig. 3c, Supplementary Fig. 3c, and Supplementary
Table 1)44. Each of these elements utilizes the NXF1 nuclear RNA
export pathway, thereby bypassing the need for CRM1 and rev45.
p24 levels with this construct were similar to those of HIV-1-
GFP, indicating that unspliced RNA was exported from the
nucleus at least as well as with Rev (Fig. 3c). Nonetheless, the
HIV-RTE/CTE vector did not mature DCs (Fig. 3c and Supple-
mentary Fig. 3c), indicating that maturation was dependent upon
rev and CRM1-mediated RNA export. Consistent with this con-
clusion, the CRM1 inhibitor leptomycin B (Supplementary
Table 2) abrogated DC maturation by HIV-1-GFP (Fig. 3d and
Supplementary Fig. 3d). In contrast, leptomycin B had no effect
on DC maturation in response to Sendai virus infection (Fig. 3e
and Supplementary Fig. 3d). ISG15 was used to monitor
maturation in these experiments since, as previously reported for
DCs, leptomycin B altered background levels of CD8646.
HIV-1 activates macrophages and CD4+ T cells. To determine if
innate immune detection of HIV-1 was unique to DCs, monocyte-
derived macrophages and CD4+ T cells were examined. In
response to transduction with HIV-1-GFP, macrophages upre-
gulated CD86, ISG15, and HLA-DR, and CD4+ T cells upregu-
lated MX1, IFIT1, and HLA-DR (Fig. 4a and Supplementary
Fig. 4a-f). DCs, macrophages, and CD4+ T cells were then
transduced side-by-side with mutant constructs to determine if the
Fig. 1 HIV-1 transduction matures DCs. a Schematic of HIV-1-GFP, with frameshift in env (red line) and gfp in place of nef29, and of the minimal lentivector,
with self-inactivating ΔU3 LTR42 and gfp driven by the SFFV promoter16. Unless indicated otherwise, vectors were pseudotyped with VSV G and cells were
co-transduced with SIVMAC251 VLPs bearing Vpx. b Flow cytometry of DCs for GFP and CD86, after treatment as indicated. c Flow cytometry histograms
for the indicated markers 72 h after DC transduction with HIV-1 (red) or mock (black). d Flow cytometry of DCs for GFP and CD86 after transduction with
single-cycle clones, HIV-1NL4-3, HIV-1AD17, HIV-1Z331M-TF, or HIV-1ZM249M. e Transduction of DCs with HIV-2ROD-GFP, single-cycle vector. f Flow cytometry
for CD86 and ISG15 of DCs treated for 24 h in the presence of nevirapine with a 1:1000 dilution of supernatant from autologous DCs transduced with the
indicated vectors. g DC transduction with HIV-1-GFP in the absence of Vpx and the presence of 2 mM nucleosides. h 12-day spreading infection on DCs,
with macrophage-tropic or T cell-tropic, replication-competent HIV-1, with or without SIV VLPs. i qRT-PCR quantitation of CXCL10 (black), IFNB1 (gray), or
IL15 (white) mRNAs from DCs transduced with HIV-1-GFP. j qRT-PCR quantitation of CXCL10 mRNA in DCs transduced with either HIV-1-GFP or minimal
lentivector, assessed at the indicated times post-transduction. k Cytokines in DC supernatant as assessed by luminex, 72 h after transduction with HIV-1-
GFP (black) or minimal lentivector (gray). Shown are blood donor data representative of n= 12 (b), n= 4 (c–k), or n= 8 (h). To determine signiﬁcance, the
MFI of all live cells for each sample was calculated as fold-change versus control. The exception being h where the MFI of only GFP+ cells was compared.
When data from each donor replicate within a experiment was combined, the difference in MFI for all experimental vs control conditions was signiﬁcant in
all cases, p < 0.01; one-way ANOVA, Dunnett’s post-test. qRT-PCR and Luminex data were mean ± SD, p < 0.0001; two-way ANOVA, Dunnett’s post-test
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mechanism of innate immune activation was similar to that in
DCs. As with DCs, HIV-1-GFP bearing the Δgag/pol deletion
activated macrophages and CD4+ T cells (Fig. 4b and Supple-
mentary Fig. 4a, d). Also in agreement with the DC results, neither
the minimal lentivector, nor HIV-1-GFP bearing mutations in
integrase, tat, or rev, matured any of the three cell types (Fig. 4b
and Supplementary Fig. 4a, d).
CD4+ T cells were infected with either macrophage-tropic or T
cell-tropic HIV-1 to determine whether replication-competent
HIV-1 was similarly capable of innate immune activation in these
cells, in the absence of VSV G. As with DCs, innate immune
activation, as detected by MX1 and ISG15 upregulation, was
observed in cells productively infected with HIV-1, but not with
minimal lentivector (Fig. 4c and Supplementary Fig. 4g, h).
Finally, to test the effect of HIV-1 proviral RNA on non-activated
T cells, CD4+ T cells were co-transduced with Tet-HIV-1 and the
rtTA3 vector, and cultured for 9 days in the absence of
stimulation. Upon doxycycline treatment, T cells expressed GFP
and MX1 (Fig. 4d and Supplementary Fig. 4i). As in DCs, dose-
dependent activation was observed with doxycycline (Fig. 4d and
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Supplementary Fig. 4i). These data indicate that innate immune
activation by HIV-1, in all three cell types, requires integration,
transcription, and Rev-dependent, HIV-1 intron-containing RNA.
Discussion
The HIV-1 LTR generates a single primary transcript that gives
rise to over 100 alternatively spliced RNAs47. The full-length,
unspliced, intron-bearing transcript acts as viral genomic RNA in
the virion and as mRNA for essential gag- and pol-encoded
proteins. Expression of the unspliced transcript requires specia-
lized viral and cellular machinery, HIV-1 Rev and CRM145, in
order to escape from processing by the spliceosome. Results here
indicate that unspliced or partially spliced HIV-1 RNA is detected
by human cells as a danger signal, as has been reported for
inefﬁciently spliced mRNAs from transposable elements in dis-
tantly related eukaryotes48. Transposable elements are mutagenic
to the host genome and it stands to reason that molecular features
such as transcripts bearing multiple, inefﬁcient splice signals
characteristic of retrotransposons, would activate innate immune
signaling pathways.
HIV-1 genomic RNA contains extensive secondary and higher
order structures that could be detected by innate immune sensors.
Our knockdown of IRF3 and inhibition of TBK1, both required
for signal transduction of the RNA sensors RIG-I, MDA5, and
TLR3, did not impede HIV-1 maturation of DCs (Fig. 2c and
Supplementary Fig. 2b). Furthermore, we suppressed an extensive
list of innate signaling pathways and sensors including knock-
downs of IRF’s 1, 5, 7, and 9, STAT’s 1 and 2, as well as phar-
macologic inhibition of CypA, PKR, c-Raf, IkBa, NF-kB, MEK1
+ 2, p38, JNK, Caspase 1, pan-Caspases, ASK1, eIF2a, IKKe,
TAK1, or NLRP3 (Supplementary Fig. 2c and Supplementary
Table 2). None of these perturbations had any effect on limiting
innate immune activation by HIV-1, suggesting requirement for
an alternative detection mechanism. Such mechanisms might
include uncharacterized RNA sensors, more than one redun-
dantly acting sensors, direct detection of stalled splicing
machinery, or overload of the CRM1 nuclear export pathway
itself.
The replication competent HIV-1 reservoir in memory CD4+
T cells has a 44 wk half-life and thus patients must take antiviral
medication for life49. Long-lived, replication competent HIV-1
reservoirs in other cell types have not been clearly demonstrated,
but these may also contribute to the HIV-1 reservoir3. The
common genetic determinants in HIV-1 for maturation of CD4+
T cells, macrophages, and DCs suggests that HIV-1 is detected by
a mechanism that is conserved across cell types, and that this
mechanism would be active in any cell type that possesses a
transcriptionally active provirus. Data here show that proviruses
need not be replication competent to contribute to inﬂammation.
Rather, HIV-1 transcription and export of unspliced RNA,
regardless of replication competence, is sufﬁcient to induce
immune activation. This almost certainly contributes to systemic
inﬂammation during acute or untreated chronic infection.
Whether inﬂammation is activated in response to provirus
expression in cells of patients on antiretroviral therapy remains to
be determined. Consistent with our ﬁndings, T cell activation
correlates directly with the level of cell-associated HIV-1 RNA
in patients receiving antiretroviral therapy50. Finally, our data
suggests that new drugs that block HIV-1 transcription,
Tat-mediated transcriptional elongation, or Rev-mediated pre-
servation of unspliced transcripts51, would limit inﬂammation,
and offer an important addition to the current anti-HIV-1 drug
armamentarium.
Methods
Data reporting. No statistical methods were used to predetermine sample size. The
experiments were not randomized. The investigators were not blinded to allocation
during experiments and outcome assessment.
Plasmids. The plasmids used here were either previously described or generated
using standard cloning methods16. The full list of plasmids used here, along with
their purpose and characteristics, is provided in Supplementary Table 1. All
plasmid DNAs with complete nucleotide sequence ﬁles are available at www.
addgene.com.
Cell culture. Cells were cultured at 37 °C in 5% CO2 humidiﬁed incubators and
monitored for mycoplasma contamination using the Lonza Mycoplasma Detection
kit by Lonza (LT07-318). HEK293 cells (ATCC) were used for viral production and
were maintained in DMEM supplemented with 10% FBS, 20 mM L-glutamine
(ThermoFisher), 25 mM HEPES pH 7.2 (SigmaAldrich), 1 mM sodium pyruvate
(ThermoFisher), and 1× MEM non-essential amino acids (ThermoFisher). Cyto-
kine conditioned media was produced from HEK293 cells stably transduced with
pAIP-hGMCSF-co (Addgene #74168), pAIP-hIL4-co (Addgene #74169), or pAIP-
hIL2 (Addgene #90513), as previously described16.
Leukopaks were obtained from anonymous, healthy, blood bank donors (New
York Biologics). As per NIH guidelines (http://grants.nih.gov/grants/policy/hs/
faqs_aps_deﬁnitions.htm), experiments with these cells were declared non-human
subjects research by the UMMS IRB. PBMCs were isolated from leukopaks by
gradient centrifugation on Histopaque-1077 (Sigma-Aldrich). CD14+
mononuclear cells were isolated via positive selection using anti-CD14 antibody
microbeads (Miltenyi). Enrichment for CD14+ cells was routinely >98%.
To generate DCs or macrophages, CD14+ cells were plated at a density of 1 to
2 × 106 cells/mL in RPMI-1640 supplemented with 5% heat inactivated human
AB+ serum (Omega Scientiﬁc, Tarzana, CA), 20 mM L-glutamine, 25 mM HEPES
pH 7.2, 1 mM sodium pyruvate, and 1× MEM non-essential amino acids (RPMI-
HS complete) in the presence of cytokines that promote differentiation. DCs were
generated by culturing monocytes for 6 days in the presence of 1:100 cytokine-
conditioned media containing human GM-CSF and human IL-4. DC preparations
were consistently >99% DC-SIGNhigh, CD11chigh, and CD14low by ﬂow cytometry.
Macrophages were generated by culturing for 7 days with GM-CSF conditioned
media in the absence of IL-4, and were routinely >99% CD11b. CD4+ T cells were
isolated from PBMCs that had been depleted of CD14+ cells, as above, using anti-
CD4 microbeads (Miltenyi), and were >99% CD4+. CD4+ T cells were then
cultured in RPMI-1640 supplemented with 10% heat inactivated FBS, 20 mM L-
Fig. 2 Native HIV-1 RNA regulation is necessary for DC maturation. a Assessment of GFP and CD86 by ﬂow cytometry following transduction with, top,
HIV-1-GFP in the presence of 5 µM nevirapine (RTi), 10 µM raltegravir (INi), or no drug, and, bottom, HIV-1-GFP bearing mutant RT-D185K/D186L (RTmut)
or mutant IN-D116A (INmut). b qRT-PCR quantitation of CXCL10 mRNA from the same DCs as a. c DCs treated with 1 µM of the TBK1 inhibitor BX795, or
expressing shRNAs targeting either IRF3 or luciferase control16, were challenged with 25 µg/mL cGAMP or HIV-1-GFP and assayed by ﬂow cytometry for
CD86 and ISG15. d Flow cytometry of DCs after transduction with minimal lentivectors expressing codon optimized HIV-1 genes; e, HIV-1-GFP in which
translation was disrupted by two frameshifts in gag or by mutation of the ﬁrst 14 AUGs in gag; f, HIV-1-GFP bearing deletion mutations encompassing
gag/pol, vif/vpr, vpu/env, or nef/U3-LTR; g, HIV-1-GFP bearing mutations in tat or rev, co-transduced with both mutants, or co-transduced with minimal
vector expressing tat and rev in trans; or h minimal lentivector with GFP in place of gag, SFFV promoter driving expression of tat, rev, or both, and repaired
U3 in the 3′ LTR. When an essential viral component was disrupted within HIV-1-GFP, the factor in question was provided in trans, either during assembly in
transfected HEK293 cells, or within transduced DCs, as appropriate (see Methods). Shown are blood donor data representative of n= 6 (a, b, e, f), n= 12
(c, g, h), n= 8 (d). To determine signiﬁcance, the MFI of individual ﬂow cytometry samples was calculated as fold-change versus control. When data from
each donor replicate within a experiment were combined, the difference in MFI for all experimental vs control conditions was signiﬁcant in all cases, p <
0.01; one-way ANOVA, Dunnett’s post-test against HIV-1-GFP for a, c, d, h or lentivector control for e, f. qRT-PCR data are mean±SD (p < 0.0001; two-way
ANOVA, Dunnett’s post-test)
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glutamine, 25 mM HEPES pH 7.2, 1 mM sodium pyruvate, 1× MEM non-essential
amino acids (RPMI-FBS complete), and 1:2000 IL-2 conditioned media. Cells from
particular donors were excluded from experiments if percent enrichment deviated
more than 5% from the numbers mentioned above, or if there was no increase in
activation markers in response to control stimuli (LPS, Sendai virus, and wild-type
HIV-1-GFP).
HIV-1 vector production. HEK293E cells were seeded at 75% conﬂuency in six-
well plates and transfected with 6.25μL Transit LT1 lipid reagent (Mirus) in 250 μL
Opti-MEM (Gibco) with 2.25 µg total plasmid DNA. 2-part HIV-1 vectors based
on HIV-1-GFP29 and described in detail in Supplementary Table 1 were
transfected at a 7:1 ratio in terms of µgs of HIV-1 plasmid DNA to pMD2.G VSV
G expression plasmid DNA16. Three-part lentivectors were produced by trans-
fection of the lentivector genome, psPAX2 GagPol vector, and pMD2.G, at a DNA
ratio of 4:3:1. These also include 2-part HIV-1-GFP constructs that are mutated in
such a way as to prevent GagPol, Tat, or Rev production. As these would be
defective for viral production, psPAX2 was included in the transfections at the
same 4:3:1 ratio. VPX-bearing SIV-VLPs were produced by transfection at a 7:1
plasmid ratio of SIV3+ to pMD2.G16. Twelve hours after transfection, media was
changed to the speciﬁc media for the cells that were to be transduced. Viral
supernatant was harvested 2 days later, ﬁltered through a 0.45 µm ﬁlter, and stored
at 4 °C.
Virions in the transfection supernatant were quantiﬁed by a PCR-based assay
for reverse transcriptase activity16. Five microliter transfection supernatant were
lysed in 5 μL 0.25% Triton X-100, 50 mM KCl, 100 mM Tris-HCl pH 7.4, and 0.4
U/μL RNase inhibitor (RiboLock, ThermoFisher). Viral lysate was then diluted
1:100 in a buffer of 5 mM (NH4)2SO4, 20 mM KCl, and 20 mM Tris–HCl pH 8.3.
10 μL was then added to a single-step, RT PCR assay with 35 nM MS2 RNA (IDT)
as template, 500 nM of each primer (5′-TCCTGCTCAACTTCCTGTCGAG-3′ and
5′-CACAGGTCAAACCTCCTAGGAATG-3′), and hot-start Taq (Promega) in a
buffer of 20 mM Tris-Cl pH 8.3, 5 mM (NH4)2SO4, 20 mM KCl, 5 mM MgCl2, 0.1
mg/mL BSA, 1/20,000 SYBR Green I (Invitrogen), and 200 μM dNTPs. The RT-
PCR reaction was carried out in a Biorad CFX96 cycler with the following
parameters: 42 °C 20 min, 95 °C 2min, and 40 cycles [95 °C for 5 s, 60 °C 5 s, 72 °C
for 15 s and acquisition at 80 °C for 5 s]. Two-part vectors typically yielded 107 RT
units/µL, and 3 part vector transfections yielded 106 RT units/µL.
Transductions. 106 DCs/mL, or 5 × 105 macrophages/mL, were plated into RPMI-
HS complete with Vpx+ SIV-VLP transfection supernatant added at a dilution of
1:6. After 2 h, 108 RT units of viral vector was added. In some cases, drugs were
added to the culture media as speciﬁed in Supplementary Table 2. In most cases,
transduced DC were harvested for analysis 3 days following challenge. For gene
knockdown or for expression of factors in trans, 2 × 106 CD14+ monocytes/mL
were transduced directly following magnetic bead isolation with 1:6 volume of SIV-
VLPs and 1:6 volume of vector. When drug selection was required, 4 µg/mL
puromycin was added 3 days after monocyte transduction and cells were selected
for 3 days. SIV-VLPs were re-administered in all cases with HIV-1 or lentivector
challenge. For DCs in Tet-HIV-1 experiments, fresh monocytes were SIV-VLP
treated and co-transduced with rtTA3 and Tet-HIV-1. DCs were harvested 6 days
later and treated with indicated doxycycline concentrations.
For deoxynucleoside-assisted transductions, DCs were plated at 106 DCs/mL
and treated with 2 mM of combined deoxynucleosides for 2 h before transduction
with HIV-1. Deoxynucleosides were purchased from Sigma-Aldrich (2′
deoxyguanosine monohydrate, cat# D0901; thymidine, cat# T1895; 2′
deoxyadenosine monohydrate, cat# D8668; 2′deoxycytidine hydrochloride, cat#
D0776). A 100 mM stock solution was prepared by dissolving each of the four
nucleotides at 100 mM in RPMI 1640 by heating the medium at 80 °C for 15 min.
CD4+ T cells were stimulated in RPMI-FBS complete with 1:2000 hIL-2
conditioned media and 5 μg/mL PHA-P. After 3 days, T cells were replated at 106
cells/mL in RPMI-FBS complete with hIL-2. Cells were transduced with 108 RT
units of viral vector per 106 cells and assayed 3 days later. T cells were co-
transduced with rtTA3 and Tet-HIV-1 every day for 3 days after PHA stimulation.
Cells were then replated in RPMI-FBS complete with hIL-2. Transduced T cells
Fig. 3 Rev-mediated RNA export is necessary for DC maturation but Tat is
dispensable. a Optimized 2xTet operator43 was cloned into the 3’LTR of
HIV-1-GFPΔtat to generate Tet-HIV-1; the strand-transfer reactions that
occur during reverse transcription generate a Tet-regulated 5′-LTR in the
provirus. DCs transduced with Tet-HIV-1, rtTA3, or both, were treated for
3 d with 500 ng/mL doxycycline and assayed by ﬂow cytometry for p24,
GFP, and CD86. b DCs co-transduced with Tet-HIV-1 and rtTA3 were
treated with increasing concentrations of doxycycline. c To generate HIV-1-
RTE/CTE, the RTEm26CTE element44 was cloned in place of nef in HIV-1-
GFPΔrev/ΔRRE. DCs were transduced with the indicated vectors and
assessed for p24 and ISG15 by ﬂow cytometry. d DCs were treated with 25
nM leptomycin B, transduced with HIV-1-GFP, and assessed for GFP and
ISG15 by ﬂow cytometry. e DCs were treated with 25 nM leptomycin B,
transduced with HIV-1-GFP or infected with Sendai virus (SeV), and
assessed for ISG15 by ﬂow cytometry. Shown are blood donor data
representative of n= 10 (a, c), n= 4 (b), n= 6 (d, e). To determine
signiﬁcance, the MFI of individual ﬂow cytometry samples was calculated as
fold-change versus control. When data from each donor replicate within a
experiment was combined, the difference in MFI for all experimental vs
control conditions was signiﬁcant in all cases, p < 0.01; one-way ANOVA,
Dunnett’s post-test against dox negative control for a, b or HIV-1-GFP for c–e
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were cultured for 9 days with fresh media added at day 5. After 9 days, doxycycline
was added at the indicated concentrations and assayed 3 days later.
Non-HIV-1 challenge viruses. Sendai Virus Cantell Strain was purchased from
Charles River Laboratories. Infections were performed with 200 HA units/mL on
DCs for 3 days before assay by ﬂow cytometry.
Spreading infections. DCs were plated at 106 DCs/mL, in RPMI-HS complete
media, with or without Vpx+ SIV-VLP transfection supernatant added at a dilution
of 1:6. After 2 h, 108 RT units of HEK-293 transfection supernatant of either NL4-
3-GFP-JRFL or NL4-3-GFP-JRCSF was added. Each is a construct of pNL4-3 in
which env was replaced from the end of the signal peptide (therefore retaining the
NL4-3 signal peptide and Vpu sequence) to the stop codon with either
macrophage-tropic JR-FL env (GenBank: U63632.1) or T cell-tropic JR-CSF env
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(GenBank: M38429.1). Every 3 days (for a total of 12 days) samples were harvested
for detection of viral RT activity in supernatant and ﬂow cytometry assessment.
CD4+ T cells were stimulated in RPMI-FBS complete with 1:2000 hIL-2
conditioned media and 5 μg/mL PHA-P. After 3 days, T cells were replated at 106
cells/mL in RPMI-FBS complete with hIL-2 and transduced with 107 RT units of
NL4-3-GFP with JRFL (mac tropic) or JRCSF (T tropic) env. Cells were harvested
every 3 days (for a total of 12 days) and assayed for infectivity and activation via
ﬂow cytometry.
Supernatant transfer experiments. Supernatant from HIV-1-GFP and minimal
lentivector challenged DCs was harvested 3 days post transduction. This was
centrifuged at 500 × g for 5 mins and ﬁltered through a 0.45 μm ﬁlter to remove cell
debris. DCs of the same individual donors were then treated with the harvested
supernatant at a dilution of 1:1000 (1 μL in 1 mL of culture). This was performed in
the presence of nevirapine to inhibit secondary infection from remaining, cell free
virions. Treatments of supernatants of HIV-1 challenged DCs were compared
directly to unchallenged DC supernatant treatments.
Cytokine analysis. Supernatants from DCs were collected 3 days following
transduction with HIV-1-GFP or minimal lentivector. Supernatant was spun at
500 × g for 5 mins and ﬁltered through a 0.45 μm ﬁlter. Multiplex soluble protein
analysis was carried out by Eve Technologies (Calgary, AB, Canada).
qRT-PCR. Total RNA was isolated from 5 × 105 DCs using RNeasy Plus Mini
(Qiagen) with Turbo DNase (ThermoFisher) treatment between washes. First-
strand synthesis used Superscript III Vilo Master mix (Invitrogen) with random
hexamers. qPCR was performed in 20 μL using 1× TaqMan Gene Expression
Master Mix (Applied Biosystems), 1 μL cDNA, and 1 μL TaqMan Gene Expression
Assays (ThermoFisher) speciﬁed in Supplementary Table 3. Ampliﬁcation was on a
CFX96 Real Time Thermal Cycler (Bio-Rad) using the following program: 95 °C
for 10 min [45 cycles of 95 °C for 15 s and 60 °C for 60 s]. Housekeeping gene
OAZ1 was used as control16.
Flow cytometry. 105 cells were surface stained in FACS buffer (PBS, 2% FBS, 0.1%
Sodium Azide), using the antibodies in Supplementary Table 4. All antibodies were
used at a dilution of 1:100 with the exception of the p24 antibody (KC57 Beck-
manCoulter) which was used at a 1:200 dilution. Cells were then ﬁxed in a 1:4
dilution of BD Fixation Buffer and assayed on a BD C6 Accuri. BD Biosciences
Fixation and Permeabilization buffers were utilized for intracellular staining. Data
was analyzed in FlowJo.
Sampling. All individual experiments were performed with biological duplicates,
using cells isolated from two different blood donors. Flow cytometry plots in the
ﬁgures show representative data taken from experiments performed with cells from
the number of donors indicated in the ﬁgure legends.
Statistical analysis. Experimental n values and information regarding speciﬁc
statistical tests can be found in the ﬁgure legends. The mean ﬂuorescence intensity
for all live cells analyzed under a given condition was calculated as fold-change to
negative control/mock. The exception to this methodology was in Figs. 1g and 4c
where the percent infected cells was too low to use MFI for the bulk population; in
these cases MFI was determined for the subset of cells within the GFP+ gate.
Signiﬁcance of ﬂow cytometry data was determined via one-way ANOVA. A
Dunnett’s post-test for multiple comparisons was applied, where MFI fold change
was compared to either mock treatment or positive treatment depending on the
experimental question. qRT-PCR and luminex data was analyzed via two-way
Anova, with Dunnett’s post-test comparing all samples to mock. All ANOVAs
were performed using PRISM 7.02 software (GraphPad Software, La Jolla, CA).
Data availability
The plasmids described in Supplementary Table 1, along with their complete
nucleotide sequences, are available at www.addgene.com. The data that support the
ﬁndings of this study are available from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary
Information ﬁle.
Received: 1 May 2018 Accepted: 21 November 2018
References
1. Arts, E. J. & Hazuda, D. J. HIV-1 antiretroviral drug therapy. Cold Spring
Harb. Perspect. Med. 2, a007161 (2012).
2. Günthard, H. F. et al. Antiretroviral drugs for treatment and prevention of
HIV infection in adults: 2016 recommendations of the International Antiviral
Society-USA Panel. JAMA 316, 191–210 (2016).
3. Kandathil, A. J., Sugawara, S. & Balagopal, A. Are T cells the only HIV-1
reservoir? Retrovirology 13, 86 (2016).
4. Siliciano, J. D. et al. Long-term follow-up studies conﬁrm the stability of the
latent reservoir for HIV-1 in resting CD4+T cells. Nat. Med. 9, 727–728
(2003).
5. Jiang, A.-P. et al. Human mucosal mast cells capture HIV-1 and mediate viral
trans-infection of CD4+T cells. J. Virol. 90, 2928–2937 (2015).
6. Davey, R. T. Jr et al. HIV-1 and T cell dynamics after interruption of highly
active antiretroviral therapy (HAART) in patients with a history of sustained
viral suppression. Proc. Natl Acad. Sci. USA 96, 15109–15114 (1999).
7. Wang, D. et al. Evolution of drug-resistant viral populations during
interruption of antiretroviral therapy. J. Virol. 85, 6403–6415 (2011).
8. Siliciano, J. D. & Siliciano, R. F. Recent trends in HIV-1 drug resistance. Curr.
Opin. Virol. 3, 487–494 (2013).
9. Johnson, V. A. et al. Update of the drug resistance mutations in HIV-1: March
2013. Top. Antivir. Med. 21, 6–14 (2013).
10. Freiberg, M. S. et al. HIV infection and the risk of acute myocardial infarction.
JAMA Intern. Med. 173, 614–622 (2013).
11. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune
activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).
12. Sinha, A. et al. Role of T-cell dysfunction, inﬂammation, and coagulation in
microvascular disease in HIV. J. Am. Heart Assoc. 5, e004243 (2016).
13. Bruner, K. M. et al. Defective proviruses rapidly accumulate during acute
HIV-1 infection. Nat. Med. 22, 1043–1049 (2016).
14. Wiegand, A. et al. Single-cell analysis of HIV-1 transcriptional activity reveals
expression of proviruses in expanded clones during ART. Proc. Natl Acad. Sci.
USA 114, E3659–E3668 (2017).
15. Luban, J. Innate immune sensing of HIV-1 by dendritic cells. Cell Host
Microbe 12, 408–418 (2012).
16. Pertel, T. et al. TRIM5 is an innate immune sensor for the retrovirus capsid
lattice. Nature 472, 361–365 (2011).
17. Lascano, J., Uchil, P. D., Mothes, W. & Luban, J. TRIM5 retroviral restriction
activity correlates with the ability to induce innate immune signaling. J. Virol.
90, 308–316 (2016).
18. Postler, T. S. & Desrosiers, R. C. The cytoplasmic domain of the HIV-1
glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase
1. Cell. Host. Microbe 11, 181–193 (2012).
19. Fonteneau, J.-F. et al. Human immunodeﬁciency virus type 1 activates
plasmacytoid dendritic cells and concomitantly induces the bystander
maturation of myeloid dendritic cells. J. Virol. 78, 5223–5232 (2004).
20. O’Brien, M., Manches, O. & Bhardwaj, N. Plasmacytoid dendritic cells in HIV
infection. Adv. Exp. Med. Biol. 762, 71–107 (2013).
Fig. 4 Innate immune activation in macrophages and CD4+ T cells. aMacrophages and CD4+ T cells were transduced with HIV-1-GFP and assayed 3 days
later for the indicated activation markers. b DCs, macrophages, and CD4+ T cells were challenged with HIV-1-GFP or the indicated mutants. When an
essential viral component was disrupted within HIV-1-GFP, the factor in question was provided in trans during assembly in transfected HEK293 cells, as
appropriate (see Methods). The upper panel shows ﬂow cytometry of the DCs for GFP and CD86. The histograms show CD86 for DCs and macrophages
or MX1 for CD4+ T cells. c 12-day spreading infections on CD4+ T cells with either macrophage-tropic or T cell-tropic, replication-competent HIV-1.
d CD4+ T cells were stimulated for 3 days with PHA and IL2, and transduced with Tet-HIV-1 and rtTA3. Cells were then cultured without stimulation for
9 days. Doxycycline was then added at the indicated concentrations. Cells were assayed for GFP and MX1 3 days later. Shown are blood donor data
representative of n= 6 (a), n= 4 (b–d). To determine signiﬁcance, the MFI of individual ﬂow cytometry samples was calculated as fold-change versus
control. The exception being c where the MFI of only GFP+ cells was compared. When data from each donor replicate within a experiment were combined,
the difference in MFI for all experimental vs control conditions was signiﬁcant in all cases, p < 0.01; one-way ANOVA, Dunnett’s post-test against
lentivector control for a–c or dox control for d
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07753-2 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5305 | https://doi.org/10.1038/s41467-018-07753-2 | www.nature.com/naturecommunications 9
21. Beignon, A.-S. et al. Endocytosis of HIV-1 activates plasmacytoid dendritic
cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115,
3265–3275 (2005).
22. Solis, M. et al. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection
by a protease-mediated sequestration of RIG-I. J. Virol. 85, 1224–1236 (2011).
23. Berg, R. K. et al. Genomic HIV RNA induces innate immune responses
through RIG-I-dependent sensing of secondary-structured RNA. PLoS ONE 7,
e29291 (2012).
24. Gao, D. et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV
and other retroviruses. Science 341, 903–906 (2013).
25. Vermeire, J. et al. HIV Triggers a cGAS-Dependent, Vpu- and Vpr-Regulated
Type I Interferon Response in CD4+T Cells. Cell Rep. 17, 413–424 (2016).
26. Lahaye, X. et al. The capsids of HIV-1 and HIV-2 determine immune
detection of the viral cDNA by the innate sensor cGAS in dendritic cells.
Immunity 39, 1132–1142 (2013).
27. Manel, N. et al. A cryptic sensor for HIV-1 activates antiviral innate immunity
in dendritic cells. Nature 467, 214–217 (2010).
28. Gringhuis, S. I., et al HIV-1 blocks the signaling adaptor MAVS to evade
antiviral host defense after sensing of abortive HIV-1 RNA by the host
helicase DDX3. Nat. Immunol. 18, 225–235 (2017).
29. He, J. et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
Nature 385, 645–649 (1997).
30. Landau, N. R. The innate immune response to HIV-1: to sense or not to sense.
DNA Cell Biol. 33, 271–274 (2014).
31. Rasaiyaah, J. et al. HIV-1 evades innate immune recognition through speciﬁc
cofactor recruitment. Nature 503, 402–405 (2013).
32. Goujon, C. et al. With a little help from a friend: increasing HIV transduction
of monocyte-derived dendritic cells with virion-like particles of SIV(MAC).
Gene Ther. 13, 991–994 (2006).
33. Reis e Sousa, C. Dendritic cells in a mature age. Nat. Rev. Immunol. 6,
476–483 (2006).
34. Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc.
Natl Acad. Sci. USA 110, 6626–6633 (2013).
35. Deymier, M. J. et al. Heterosexual transmission of subtype C HIV-1 selects
consensus-like variants without increased replicative capacity or interferon-α
resistance. PLoS Pathog. 11, e1005154 (2015).
36. Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and
evolutionary pathways of transmitted/founder viruses in acute and early HIV-
1 infection. J. Exp. Med. 206, 1273–1289 (2009).
37. Reinhard, C., Bottinelli, D., Kim, B. & Luban, J. Vpx rescue of HIV-1 from the
antiviral state in mature dendritic cells is independent of the intracellular
deoxynucleotide concentration. Retrovirology 11, 12 (2014).
38. Granelli-Piperno, A., Delgado, E., Finkel, V., Paxton, W. & Steinman, R. M.
Immature dendritic cells selectively replicate macrophagetropic (M-Tropic)
human immunodeﬁciency virus type 1, while mature cells efﬁciently transmit
both M- and T-tropic virus to T cells. J. Virol. 72, 2733–2737 (1998).
39. De Iaco, A. & Luban, J. Inhibition of HIV-1 infection by TNPO3 depletion is
determined by capsid and detectable after viral cDNA enters the nucleus.
Retrovirology 8, 98 (2011).
40. Henderson, G. J. et al. Interplay between single resistance-associated
mutations in the HIV-1 protease and viral infectivity, protease activity, and
inhibitor sensitivity. Antimicrob. Agents Chemother. 56, 623–633 (2012).
41. Craigie, R. & Bushman, F. D. HIV DNA integration. Cold Spring Harb.
Perspect. Med. 2, a006890 (2012).
42. Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efﬁcient
in vivo gene delivery. J. Virol. 72, 9873–9880 (1998).
43. Das, A. T. & Berkhout, B. Conditionally replicating HIV and SIV variants.
Virus Res. 216, 66–75 (2016).
44. Smulevitch, S. et al. RTE and CTE mRNA export elements synergistically
increase expression of unstable, Rev-dependent HIV and SIV mRNAs.
Retrovirology 3, 1–9 (2006).
45. Fornerod, M., Ohno, M., Yoshida, M. & Mattaj, I. W. CRM1 is an export
receptor for leucine-rich nuclear export signals. Cell 90, 1051–1060 (1997).
46. Chemnitz, J., Turza, N., Hauber, I., Steinkasserer, A. & Hauber, J. The
karyopherin CRM1 is required for dendritic cell maturation. Immunobiology
215, 370–379 (2010).
47. Ocwieja, K. E. et al. Dynamic regulation of HIV-1 mRNA populations
analyzed by single-molecule enrichment and long-read sequencing. Nucleic
Acids Res. 40, 10345–10355 (2012).
48. Dumesic, P. A. et al. Stalled spliceosomes are a signal for RNAi-mediated
genome defense. Cell 152, 957–968 (2013).
49. Crooks, A. M. et al. Precise quantitation of the latent HIV-1 reservoir:
implications for eradication strategies. J. Infect. Dis. 212, 1361–1365
(2015).
50. El-Diwany, R. et al. Intracellular HIV-1 RNA and CD4+T-cell activation in
patients starting antiretrovirals. AIDS 31, 1405–1414 (2017).
51. Mousseau, G. et al. The Tat inhibitor didehydro-cortistatin A prevents HIV-1
reactivation from latency. mBio 6, e00465 (2015).
Acknowledgements
We thank the 290 anonymous blood donors who contributed leukocytes to this project,
and Ben Berkhout, Abraham Brass, Barbara Felber, Beatrice Hahn, Eric Hunter, Massimo
Pizzato, and Didier Trono for reagents. This work was supported by NIH Grants
5R01AI111809, 5DP1DA034990, and 1R01AI117839, to J.L.
Author contributions
S.M.M. and J.L. designed the experiments and S.M.M., K.K., A.D., A.N., L.Y., and W.E.D.
conducted them. All authors analyzed the data and S.M.M. and J.L. wrote the
manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-07753-2.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07753-2
10 NATURE COMMUNICATIONS |          (2018) 9:5305 | https://doi.org/10.1038/s41467-018-07753-2 | www.nature.com/naturecommunications
